Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 23Carcinoma, Non-Small-Cell Lung 8Triple Negative Breast Neoplasms 5Neoplasm Metastasis 5Colorectal Neoplasms 5Lung Neoplasms 4Breast Neoplasms, Male 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mesothelioma 2Melanoma 2Head and Neck Neoplasms 2Carcinoma, Renal Cell 2Sarcoma 1Salivary Gland Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1NSCLC 1Mesothelioma, Malignant 1Meningeal Carcinomatosis 1Lymphoma, Non-Hodgkin 1Lymphoma 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Esthesioneuroblastoma, Olfactory 1Esophageal Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

trametinib 1talimogene laherparepvec 1spartalizumab 1pembrolizumab 1nazartinib 1exemestane 1canakinumab 1Telomerase 1Tamoxifen 1Surgical Procedures, Operative 1Sentinel Lymph Node Biopsy 1Pemetrexed 1Paclitaxel 1Mastectomy, Subcutaneous 1Mastectomy, Segmental 1Mammaplasty 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Ductal × Pemetrexed × Breast × Clear all
NCT00106002 2009-06-01

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Eli Lilly and Company

Phase 2 Completed
37 enrolled 9 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡